Given the permissive predisposition of ZIKV to CD24-expressing targets, this approach also offers the opportunity to address progenitor cells involved in a broad array of cancers, not only in the pediatric field but among adult CD24-expressing cancers as well. Here, CD24 is linked to cancer.